Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIGB 540
- Development stage
- Preclinical
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Peptides
01
Overview
CIGB 540 is an experimental anti-fibrotic peptide developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. It is specifically designed for the treatment and prevention of pathological skin scarring, including keloids and hypertrophic scars. The peptide aims to modulate the fibrotic process, likely by interfering with signaling pathways that drive excessive collagen deposition and fibroblast activation, although its specific molecular target is not publicly disclosed in high-level pipeline summaries. It is currently in the preclinical stage of development.
- Other names
- antifibrotic peptide CIGB-540
02
Targets
COMMD1 (COMM domain-containing protein 1)
Beyond the preview
Go deeper on CIGB 540.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIGB 540.